Latest Conference Content

Timothy O'Shea, PharmD, MS, discussed the most surprising findings from a home infusion pilot program and explained how he thinks home infusion will continue to evolve.

Helen Shih, MD, MS, MPH, FASTRO, Massachusetts General Hospital, weighs the risks and benefits of treating or postponing treatment of low-grade gliomas.

Tina Cascone, MD, PhD, of the University of Texas MD Anderson Cancer Center, discusses the impact of the CheckMate 77T study on the treatment approach for non–small cell lung cancer (NSCLC).

Datopotamab deruxtecan not only demonstrated a statistically significant improvement over chemotherapy for breast cancer and docetaxel for non–small cell lung cancer (NSCLC), but the intervention therapy had less toxicity.

Psoriasis status from time of diagnosis to initiation of current treatment was less favorable for patients with mild psoriasis compared with moderate psoriasis, according to one study.

Christina Barrington, PharmD, of Priority Health, explained the keys to leading a successful managed care organization, as well as where she predicts the industry will be in the future.

Thomas Powles, MD, MBBS, MRCP, from Barts Cancer Centre, shares insights from the EV-302/KEYNOTE-A39 trial and its implications for the future of enfortumab vedotin and pembrolizumab (EV+P) combination therapy for urothelial carcinoma.

Enfortumab vedotin plus pembrolizumab not only beat chemotherapy in the first-line setting for locally advanced metastatic urothelial cancer for the first time in decades, but it nearly doubled progression-free survival and overall survival vs chemotherapy.

There are many drugs that have been around for years and others with strong data awaiting FDA approval that are beneficial in treating conditions like atopic dermatitis and alopecia areata, said James Q. Del Rosso, DO.

Posters presented at Fall Clinical Dermatology 2023 found that dupilumab had effective and safe results when received in a 5-year period for atopic dermatitis.

A panel discussion that took place at the 2023 Fall Clinical Dermatology Conference focused on the importance of information to treat both vitiligo and atopic dermatitis.

Regardless of presence of brain metastases, patients with HER2-mutant (HER2m) non–small cell lung cancer (NSCLC) showed systemic responses to trastuzumab deruxtecan. In addition, the therapy showed intracranial efficacy to reduce the size of brain metastases.

The results of CheckMate 77T showcase the improved event-free survival for patients with resectable non–small cell lung cancer who receive nivolumab in both the neoadjuvant and adjuvant setting and may have practice-changing implications.

With stringent criteria, randomized controlled trials are the cornerstone of cancer intervention research, but the result is they do not represent the majority of patients, which leads to a gap between the efficacy seen in trials and the effectiveness in the real-world setting.

Patients with alopecia areata found effective treatment with baricitinib, which had long-term efficacy and positive results.

Kevin Kalinsky, MD, MS, of Glenn Family Breast Center, gives insight into the real-world data supporting the use of sacituzumab govitecan-hziy in the treatment of triple-negative breast cancer (TNBC).

A panel hosted at Fall Clinical Dermatology 2023 highlighted how dermatologists can help to address acne and psoriasis in their patients.

Max Parmar, professor of medical statistics and epidemiology at University College London, unpacks what clinicians and patients can gain from the application of multiarm multistage (MAMS) trials.

Atopic dermatitis, psoriasis, and hidradenitis suppurativa (HS) can present differently in diverse patients, potentially leading to delayed diagnosis and therefore delayed treatment, explained James Song, MD, director of clinical research and associate chief medical officer at Frontier Dermatology.

Both adolescents and adults saw improvements with the use of ruxolitinib or povorcitinib to treat their nonsegmental vitiligo.

The FDA approval of topical ruxolitinib 1.5% cream changed the game for vitiligo treatment in both adult and pediatric patients, said Raj Chovatiya, MD, PhD, assistant professor of dermatology at Northwestern University's Feinberg School of Medicine.

Prerakkumar Parikh, PharmD, of Megallen Rx Management/Prime Therapeutics, detailed the impact of formulary placement of biosimilars on cost burden along with how stakeholders can work with pharmacy benefit managers to promote biosimilar use.

The phase 2 KRYSTAL-7 trial evaluated adagrasib plus pembrolizumab in patients with KRAS-mutated non–small cell lung cancer (NSCLC) with high PD-L1 expression. The results demonstrated “encouraging preliminary activity.”

“There are things more important than our discomfort, and there are things that are more important than even our fear—inclusion is more important,” said Erica Marsh, MD, MSCI. “Our care of our patients and loved ones is more important, and our existence tomorrow has to be more important than our fears today.”

A panel held at Fall Clinical Dermatology 2023 emphasized the role of Janus kinase (JAK) inhibitors in several skin conditions and highlighted new therapies in the space.

Peter A. Lio, MD, clinical assistant professor of dermatology and pediatrics at Northwestern University's Feinberg School of Medicine, addresses how dermatologists need to focus on patient needs when determining the best use of new biologics in moderate to severe atopic dermatitis.

Saira Jan, PharmD, MS, of Horizon Blue Cross Blue Shield of New Jersey, discussed the primary findings of their collaborative pilot program with Rutgers Cancer Institute of New Jersey and RWJ Barnabas Health, focusing on patient and provider experiences.

Posters presented at the American Society for Reproductive Medicine 2023 Scientific Congress & Expo highlighted trends in fertility care amid the turbulent landscape following the Dobbs decision.

Results of the monarchE study showed patients with hormone receptor–positive (HR+), HER2-negative (HER2–) high-risk, early breast cancer had greater benefit after 5 years when receiving adjuvant abemaciclib plus endocrine therapy vs endocrine therapy alone.

Posters presented at the American Society for Reproductive Medicine (ASRM) 2023 Scientific Congress & Expo addressed psychosocial symptoms and burdens faced by both embryologists and women of color with uterine fibroids.